Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions highlight how the research demonstrates a 25% reduction in initial cardiovascular events with evolocumab, using strong phrases like 'game changer' and emphasizing the significance of preventing first-time heart problems. The tone and choice of words reflect enthusiasm and a proactive attitude towards integrating these findings into clinical decisions, pointing to high interest and perceived impact.
Most discussions support the significance and positive outcomes of the study, emphasizing its potential to change preventive strategies.
The posts demonstrate high interest, with many referencing detailed trial results and discussing future implications.
Postings often cite specific data, express curiosity, and question practice changes, showing deep engagement.
The discussions suggest the study could substantially influence medical practice and preventive cardiology, indicating high impact.
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
The future of heart disease is bright, with drugs and gene therapies looking like viable ways to eliminate a lot of the risk of and from it. Sources: https://t.co/4SNYUIE43b https://t.co/KO2Uq11qC7
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the (numerous) coinvestigators ☀️ https://t.co/MQW69xoPKR
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke https://t.co/kokG0llnJi
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6 #AHA25
Evolocumab, a PCSK9 inhibitor, was studied to see if it reduces the risk of major cardiovascular events in patients without prior heart attack or stroke but with atherosclerosis or diabetes and elevated LDL cholesterol…
This video discusses recent research on left atrial appendage closure as a safe and effective alternative to anticoagulation in high-risk atrial fibrillation patients. It highlights reduced bleeding complications and…
Tuesday’s Half-Day Academic Activity we enjoyed attending: “Evolocumab in Patients without a Previous Myocardial Infarction or Stroke ” Presented by: Dr. Khawlah AlShahrani, R2 Pharmacy Resident https://t.co/xobvIbowP9
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/AjPFZSP8qy
#Evolocumab in pts without a previous #AMI or #stroke -#VESALIUS-CV #RCT #PCSK9I led to a lower risk of first CV events than placebo among pts with atherosclerosis or DM without AMI/stroke
RT @estebanjodar: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/…
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/XKicHs4wGu
7c) The authors concluded, at the #LBCT and in simulpub in @NEJM at
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/isg2U1Nolw
Lowering apoB/LDL with a PCSK9 inhibitor lowers all-cause mortality in people with atherosclerosis or diabetes but no previous heart attack or stroke https://t.co/E1wS9BzPuj Honest lipid skeptics should come to Jesus.
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/rwJF81qazX
RT @pinacol: 【RCT】心筋梗塞や脳卒中のない、LDL-コレステロールが90mg/dL以上のアテローム性動脈硬化症または糖尿病の患者へのエボロクマブ投与は、プラセボ投与と比較して、MACEを減少させた。 #ペ読 https://t.co/skpNPpPuLY
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
Evolocumab dropped events from 8.0% to 6.2% That's 25% risk reduction. LDL fell 55% to a median of 45 mg/dL. Side effects? Same in both groups. Translation: early intervention is the ultimate longevity hack. DOI: 10.1056/NEJMoa2514428
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
@JohnKastelein @Amgen It's NEJM. I don't have access, sadly. Funded by Amgen, I see... If you want to send it along, I'd love to read it. https://t.co/KstmzuB2V1
【RCT】心筋梗塞や脳卒中のない、LDL-コレステロールが90mg/dL以上のアテローム性動脈硬化症または糖尿病の患者へのエボロクマブ投与は、プラセボ投与と比較して、MACEを減少させた。 #ペ読 https://t.co/skpNPpPuLY
5- VESALIUS‑CV (NEJM Evolocumab in patients without a previous Myocardial Infarction or stroke تبحث الدراسة تأثير استخدام مثبط PCSK9 لدى مرضى DM or ASCVD كوقاية أولية قبل حدوث MI or Stroke https://t.co/DHNnt8Xuib
For those interested, here’s the NEJM study (VESALIUS-CV): https://t.co/mhLqD0wCtt
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/3UBbKRWFDS
https://t.co/Nq96jGLEEj
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine #evolocumab @NEJM https://t.co/2iFnUR7V2K
In a new study, @MassGenBrigham researchers find PCSK9 inhibitor reduced risk of first heart attack, stroke. Read more from @EBohula and colleagues: https://t.co/w7LGRyKDFJ https://t.co/5X6C2nVTJ2 @NEJM https://t.co/rWeeROZCOz
New study for PCSK9 which lowers LDL-C and Lp(a) https://t.co/TwDHffRIai
心筋梗塞・脳卒中既往のない動脈硬化または糖尿病患者を対象としたRCT（VESALIUS-CV）で，エボロクマブvsプラセボ．3点MACEを減らした（HR 0.75，0.65～0.86）．4点MACEも0.81（0.73～0.89）で，安全性は同程度だった． https://t.co/Y3TdAS9tHy
RT @pnatarajanmd: VESALIUS-CV: among high-risk pts *without* prior events, evolocumab (PCSK9 mAb) led 45mg/dl lower LDL-C & 25% RRR of a *f…
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/E4mte4adaM
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/FapHqtU15O
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @cremieuxrecueil: The future of heart disease is bright, with drugs and gene therapies looking like viable ways to eliminate a lot of th…
@MarkManger Not for ezetemibe to my knowledge but very recent PCSK9 data https://t.co/wUTA4p3T3r
RT @richardhirschs1: https://t.co/HXxkA8rRA7
Repatha (evolocumab) cut first major cardiovascular events in high risk adults without prior MI or stroke (VESALIUS-CV, @NEJM). LDL lowering with PCSK9 inhibition continues to reshape prevention.
RT @gonzaeperez: VESALIUS CV - #AHA25 -12257
https://t.co/GKMhbriJoF
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/7nlfgmvvj0
https://t.co/XWHt42bbBq
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
The future of heart disease is bright, with drugs and gene therapies looking like viable ways to eliminate a lot of the risk of and from it. Sources: https://t.co/4SNYUIE43b https://t.co/KO2Uq11qC7
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
PCSK9i reduced MACE in primary prevention population, RRR 25%, ARR 1.8%, NNT~ 56. $239/mo on Goodrx. 4.5 yrs f/u X 12 months of tx X 56 ~ $722K to prevent one MACE. https://t.co/cHeKk6SE2C
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Repatha (evolocumab) just changed the game. A NEJM study shows it reduces major cardiovascular events even before the first heart attack or stroke a breakthrough in preventive cardiology. https://t.co/rVas25E7M9 #MedTwitter #cardiology #cholesterol #clinicaltrials
RT @medical_xpress: Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #science #publication #research #publications https://t.co/CAkFmbbRlI
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @medical_xpress: Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @hvanspall: In an RCT of 12.2 K patients with #atherosclerosis or #diabetes and no prior MI or stroke who were followed a median of 4.6…
@qanhje @HRH_Ted @grok what would you suppose the chances are that the results of https://t.co/8U3uh1lEe9 are pure luck with nothing to do with drug
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @medical_xpress: Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @pnatarajanmd: VESALIUS-CV: among high-risk pts *without* prior events, evolocumab (PCSK9 mAb) led 45mg/dl lower LDL-C & 25% RRR of a *f…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @BowTiedBiotech: 2026 PSCK9 Lp(a) ANGPTL3 et al. Be ready - innovation is coming, think beyond whatever you have in mind. Multifunctio…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @medical_xpress: Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @medical_xpress: Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without…
Adding evolocumab to standard care reduces the risk of first #HeartAttack or #Stroke by 25% in high-risk adults without prior cardiovascular events, according to a large clinical trial. @MassGenBrigham @nejm https://t.co/5YarGGs71u https://t.co/IdHai6WFbw
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @shashiiyengar: @ProfTimNoakes I have the same thoughts and questions as an ordinary person. If LDL is causal and the real target for C…
RT @pnatarajanmd: VESALIUS-CV: among high-risk pts *without* prior events, evolocumab (PCSK9 mAb) led 45mg/dl lower LDL-C & 25% RRR of a *f…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
抄録
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @hvanspall: In an RCT of 12.2 K patients with #atherosclerosis or #diabetes and no prior MI or stroke who were followed a median of 4.6…
RT @NEJM: Presented at #AHA25: Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
https://t.co/HXxkA8rRA7
RT @DrDerekConnolly: PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with a…
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @hvanspall: In an RCT of 12.2 K patients with #atherosclerosis or #diabetes and no prior MI or stroke who were followed a median of 4.6…
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @mirvatalasnag: #AHA2025 #Vesalius_CV 2025: Evolocumab led to a ↓ risk of 1st CV events compared w placebo among patients w ASCVD or DM…
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @EricTopol: Repatha (evolocumab), a PCSK9 blocker that lowers LDL cholesterol, reduced major adverse cardiovascular events in a large tr…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
RT @hvanspall: In an RCT of 12.2 K patients with #atherosclerosis or #diabetes and no prior MI or stroke who were followed a median of 4.6…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @pnatarajanmd: VESALIUS-CV: among high-risk pts *without* prior events, evolocumab (PCSK9 mAb) led 45mg/dl lower LDL-C & 25% RRR of a *f…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @shashiiyengar: @ProfTimNoakes I have the same thoughts and questions as an ordinary person. If LDL is causal and the real target for C…
RT @shashiiyengar: @ProfTimNoakes I have the same thoughts and questions as an ordinary person. If LDL is causal and the real target for C…
RT @NEJM: Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) https://t.co/0gPaU5…
Evolokumab (bloker PCSK9), który obniża poziom cholesterolu LDL, zmniejsza ryzyko poważnych niepożądanych zdarzeń sercowo-naczyniowych (MACE). Wraz ze statynami dostarcza to przyczynowych dowodów, że obniżanie LDL jest korzystne dla zdrowia. https://t.co/dJjq7qrUs7
RT @dramitkhera: VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @jvillacastin: Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @cristinatejerap: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @gglinskii: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/GH0…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @cristinatejerap: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/fIDQuPXnET
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/GH08u7O1Hv
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @SeguraCardio:
RT @drbennisahmed: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke PCSK9 inhibition with evolocumab led to a low…
RT @SABOURETCardio: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @cristinatejerap: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @cristinatejerap: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.…
RT @jvillacastin: Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye…
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/oZgyrzcJkU
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/cbXgKKPiex Should we change our practice based on these results? Should we intensify primary prevention strategies even further?
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/hI6zNZNJBO
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @SeguraCardio:
RT @jvillacastin: Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @SABOURETCardio: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. https://t.co/6zMpj6EpCK
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/GBGJMad5gH Interesting articles are coming. Subscribe
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @jvillacastin: Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye…
RT @jvillacastin: Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye…
RT @cristinatejerap: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.…
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @SABOURETCardio: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the…
RT @SABOURETCardio: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the…
Importante este estudio, porque demuestra “prevención primaria” en pacientes de alto riesgo con un fármaco que disminuye colesterol LDL. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/3RD37fswy8
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/JQ7sL7vqfH. @NEJM #aha2025
RT @SeguraCardio:
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://t.co/2NciC6KsND
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
RT @DrDamluji: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke #VESALIUS in online. Glad to be one of the (numerous) coinvestigators ☀️ https://t.co/MQW69xoPKR
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke https://t.co/kokG0llnJi
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6 #AHA25
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke: @NEJM @AHAScience #AHA25
... Sources: DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. Jen Spooner and 289 others ·
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. Connie Ross and 2 others. 3 reactions ·. 1 ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. Connie Ross and 2 others. 3 reactions ·. 1 ...
DOI: 10.1056/NEJMoa2512686 five open-label trials that randomly assigned patients with recent myocardial infarction, no other indications ...
This webinar, presented by nationally recognized expert Teri Romano, BSN, MBA, CMDP, will equip you with the knowledge and skills needed to ...
~~ New trials added to Cardiac Trials ~~ PCSK9 inhibition in patients without prior MI or stroke? PCSK9 inhibitors confer powerful LDLc ...
Amiodarone prophylaxis peri- open heart surgery? Atrial fibrillation is facilitated by atrial trauma and stretch in cardiac surgery. This key ...
... 10.1056/NEJMoa2514428) publizierten Ergebnisse dürften zu einer Erweiterung der Indikation führen. rme. Zum Weiterlesen anmelden. Liebe ...
En ny studie visar att PCSK9-hämmaren evolokumab minskar risken för hjärt-kärlkomplikationer hos patienter utan tidigare hjärtinfarkt eller ...
New trials added to Cardiac Trials ~~ PCSK9 inhibition in patients without prior MI or stroke? PCSK9 inhibitors confer powerful LDLc ...
Evolocumab組的3P MACE 顯著下降25%， 4P MACE顯著下降19%。 Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more.
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. November 11 · allison.dr.lu's profile picture. allison.dr.lu. •. Follow.
A new study published in JACC investigates the connection between lipoprotein(a) and interleukin-6 with atherosclerotic cardiovascular ...
... 下降25%， 4P MACE顯著下降19%。 Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. November 11. caitlinlin238. •. Follow.
... a la terapia de vanguardia. https://www.nejm.org/doi/full/10.1056/NEJMoa2514428?query=featured_home. more. November 10 · cardioalejandro. •.
DOI: 10.1056/NEJMoa2514428 https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 Thank you so much in advance, kind regards.
... 10.1056/NEjMoa2514428 2025 Massachusetts Medical Society,. Recent Posts. Dr. Osmar Cardiólogo is at Clínica del Country. 5d
VESALIUS-CV trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 · CORAL REEF trial. Newsletter. Stay informed on drug updates, treatment ...
Hey Buddy, seriously? Most coffee is loaded with mold toxins and leaves you crashing before noon. When you use clean, mold-free beans and ...
Dave Asprey talks with Dr. Sten Stray-Gundersen about how even brief reductions in airflow affect brain function, performance, and long-term ...
What if you could reduce your heart attack risk to zero? A massive NEJM study just proved what high performers have tracked for years: lower ...
Your doctor has been tracking your total cholesterol for years. But what if there's a simple calculation that's far more predictive of heart ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. NEJM.ORG. Evolocumab in ...
org/10.1056/NEJMoa2514428. nejm.org. Evolocumab in Patients without a Previous Myocardial Infarction or. on Fri. Chito Saludes. For senior with ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. NEJM.ORG. Evolocumab in ...
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. November 11 · caitlinlin238's profile picture. caitlinlin238. •. Follow.
org/doi/full/10.1056/NEJMoa2514428 Vi er stolte over at bidrage til ny viden, der kan få betydning for hjertepatienter i hele verden ...
... 組的3P MACE 顯著下降25%， 4P MACE顯著下降19%。 Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428".
(2025). Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. DOI: 10.1056/NEJMoa2514428, https://www.nejm.
org/doi/full/10.1056/NEJMoa2514428. nejm.org. Evolocumab in Patients without a Previous Myocardial Infarction or. 1 mo. 1. Ryszard Łęt.
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM.
2025; DOI: 10.1056/NEJMoa2514428. Secondary Source. New England Journal of Medicine. Source Reference: Ndumele CE, Blumenthal RS "VESALIUS and ...
Die Studie Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (NEJM, DOI 10.1056/NEJMoa2514428) wurde von der Firma Amgen ...
... alles in einem ca. 5 Jahreszeitraum berechnet. Quelle: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 · HorrorBrot. • vor 1 Monat.
Bohula EA et al. “Evolocumab in Patients without Prior Myocardial Infarction or Stroke” NEJM DOI: 10.1056/NEJMoa2514428. ###. About Mass ...
doi:10.1056/NEJMoa2514428. Newsletter. Join thousands of clinicians staying current on new therapies, trial data, and expert insights ...
2025;doi:10.1056/NEJMoa2514428. Amgen's Repatha cuts risk of first major adverse cardiovascular events by 25% in landmark phase 3 VESALIUS ...
org/doi/full/10.1056/NEJMoa2514428 Vi er stolte over at bidrage til ny viden, der kan få betydning for hjertepatienter i hele verden ...
org/doi/full/10.1056/NEJMoa2514428 Vi er stolte over at bidrage til ny viden, der kan få betydning for hjertepatienter i hele verden ...
org/doi/full/10.1056/NEJMoa2514428. nejm.org. Evolocumab in Patients without a Previous Myocardial Infarction or. Bartosz Fiałek
圖片來自： DOI: 10.1056/NEJMoa2514428. 小兔子醫師的修煉大冒險. 22h
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. Connie Ross and 2 others.
EVs from AS patients induced calcification through expression of the pro-osteogenic genes osteocalcin and osteopontin with corresponding ...
384 likes, 0 comments - cardiactrials on September 21, 2025: "~~ New trials added to Cardiac Trials ~~ #2025 DAPT following acute coronary ...
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 138 comments. 4 days ago · drstephenhussey's profile ...
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 160 comments. November 22 · drstephenhussey's profile ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. NEJM.ORG. Evolocumab in ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. Connie Ross and 2 others.
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. November 11 · i.newsforpharm's profile picture. i.newsforpharm. •. Follow.
119 likes, 1 comments - cardiactrials on May 7, 2025: "PCI to improve symptoms in stable angina? This #AHA23 trial reaffirmed the role PCI ...
210 likes, 0 comments - cardiactrials on May 1, 2025: "Beta blockers for obstructive HCM? Negative inotropes (beta blockers, calcium channel ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. 1 day ago · professor_yuri_zakharov's profile picture · professor_yuri_zakharov. •.
org/doi/full/10.1056/NEJMoa2514428 Vi er stolte over at bidrage til ny viden, der kan få betydning for hjertepatienter i hele verden ...
anamendesbarbosa on March 25, 2025: " Definição hipercalemia ✓ Concentração sérica de potássio > 5,5mEq/L. ✓ Pode chegar a 6,5mEq/L em RN e ...
Há dois tipos de hiperglicemia que podem ser identificadas na gestação: o diabete mellitus diagnosticado na gestação (DMDG) e o diabete mellitus ...
508 likes, 3 comments - cardiactrials on March 13, 2025: "Just 1 month of DAPT after ACS? This trial showed ticagrelor monotherapy after ...
Rilonacept for recurrent pericarditis? This trial showed Rilonacept, an IL-1 inhibitor, to reduce symptoms and recurrence episodes in patients ...
This trial showed SGLT2 inhibitors to have benefit with EF > 40%, REGARDLESS of diabetes status. HFpEF represents a population of patients that beyond diuretic ...
Clopidogrel as secondary prevention monoTx? This trial (published when clopidogrel was not yet generic) showed improved outcomes over ...
Https://stephenbhussey.com/register Sources: DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. Stephen McCarthy and ...
Pretreating ACS with prasugrel before delineating coronary anatomy in the cath lab? Increases bleeding WITHOUT a difference in ischemic events.
This trial showed preventative PCI in non-flow limiting but “vulnerable” coronary plaques — ie those with a necrotic, lipid-rich core surrounded ...
Esta família viral possui como material genético uma dupla fita linear de DNA, codificando em seu genoma as proteínas necessárias para ...
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 183 comments. November 22 · drstephenhussey's profile ...
This trial showed similar positive outcomes in those without a prior vascular event — further spreading the reach of these powerful drugs to ...
Cardiac resynchronization therapy for HFrEF? Widened QRS suggests ventricular asynchrony. BiV pacing, with one lead in the RV and the other ...
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 190 comments. November 22 · drstephenhussey's profile ...
org/doi/full/10.1056/NEJMoa2514428. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM. Connie Ross and 2 others.
How strict should our heart rate control goals be when rate controlling atrial fibrillation? Lenient control (resting HR < 110 bpm) was as good ...
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 171 comments. November 22 · drstephenhussey's profile ...
This landmark trial established bisoprolol as one of 3 heart failure specific beta blockers (alongside carvedilol and metoprolol succinate), all of which with ...
Amiodarone prophylaxis peri- open heart surgery? Atrial fibrillation is facilitated by atrial trauma and stretch in cardiac surgery. This key ...
445 likes, 1 comments - cardiactrials on August 28, 2023: "~~ NEW #2023 TRIAL from the ESC conference ~~ Catheter afib ablation in patients ...
org/doi/full/10.1056/NEJMoa2514428. nejm.org. Evolocumab in Patients without a Previous Myocardial Infarction or. Bartosz Fiałek
Negative inotropes (beta blockers, ca channel blockers, or disopyramide) are the standard of care for patients with symptomatic HCM and outflow ...
org/doi/full/10.1056/NEJMoa2514428. nejm.org. Evolocumab in Patients without a Previous Myocardial Infarction or. Bartosz Fiałek
... www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. 10 hours ago · professor_yuri_zakharov's profile picture. professor_yuri_zakharov. •. Follow.
DOI: 10.1056/NEJMoa2514428 PMID's: 36585131, 29334796, 32597252, 30198808. more. View all 173 comments. November 22 · drstephenhussey's profile ...
The results of this key trial mirror those of dapagliflozin in DAPA-HF (2019), again showing mortality reduction in heart failure patients ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428. more. 1 day ago · professor_yuri_zakharov's profile picture. professor_yuri_zakharov. •.
You can now find Bulletproof products at all The Vitamin Shoppe locations! Visit your local store and check out the spread.
AP
C
S
AM
DR
PR
BM
RL
DN
EG
CM
MY
HG
Fا
F
SM
P
DA
EJ
TG
P
حH
DR
A
JS
J
JN
MR
RT
南P
O
VH
SG
AC
C
DG
PC
RR
J
JG
VP
T
ZF
DJ
BF
MF
MM
VS
JN
R
FB
Wا
DS
MM
VG
MC
LE
SG
NW
NR
A
RM
A
MR
NS
A
KP
Sシ
OM
จอ
CH
M
PS
K
AG
BZ
H
S
MX
S
BM
HM
AT
JB
LM
FD
S
HM
EC
OH
宇T
MB
CE
BF
HR
VA
A
CK
DH
C
NK
FM
JM
Rع
DK
M
C
RR
DM
AV
LM
TM
CG
CH
AL
SC
J
LM
S
SF
DR
K
RF
DM
LR
N
MP
MM
IL
TM
KD
NR
DD
V
CP
LM
DL
HM
DM
G
AM
A
ET
DV
AN
JF
VA
PM
BL
IM
KN
AC
ER
را
SM
KF
IT
BP
GP
CM
JL
GK
M
PM
JV
MG
CT
AV
FF
は心
PL